[Silencing of PKG1 expression enhances the efficacy of vemurafenib against melanoma cell].

OBJECTIVE: To explore whether targeting phosphoglycerate kinase 1 (PGK1) can enhance the sensitivity of BRAFV600E mutation melanoma cells to vemurafenib. METHODS: The methods of cell biology, molecular biology and pharmacology(MTT assay, Western blot, FCM, Colongenic assay) were used in this study. RESULTS: ① Silencing of PGK1 expression increased the efficacy of vemurafenib in melanoma cells, as evidenced by greater killing in the tumor cells subjected to combined treatment of vemurafenib with siPGK1; ②The mechanism of enhanced sensitivity of melanoma cells to vemurafenib was associated with activation of apoptotic signaling pathway. CONCLUSIONS: Targeting of PGK1 may represent a novel strategy of sensitizing melanoma cells to vemurafinib.